Search

A recent study conducted at Fudan University Obstetrics and Gynecology Hospital in Shanghai, China, aimed to develop a predictive tool for identifying patients with endometrial atypical hyperplasia (EAH) who are at high risk of concurrent endometrial cancer (EC) before surgery. The researchers established a nomogram based on three independent predictors: human epididymis protein 4 (HE4) levels, body mass index (BMI), and menopausal status. The nomogram demonstrated improved predictive value compared to individual factors and could help clinicians better manage high-risk patients. This study provides valuable insights for risk stratification and clinical decision-making in patients with EAH. [Extracted from the article]

A study conducted by researchers at the University of Texas Southwestern Medical Center investigated the predictive value of biomarkers PTEN, PAX2, and beta-catenin for therapeutic outcomes in patients with atypical endometrial hyperplasia or endometrioid intraepithelial neoplasia undergoing progestin therapy. The study analyzed 351 endometrial biopsy samples from 128 patients and categorized outcomes into responders (absence of residual disease) and nonresponders (presence of residual disease). The researchers found that aberrant biomarker expression in pretreatment cases was associated with a higher likelihood of treatment failure. The study highlights the utility of this 3-marker panel in assessing residual disease status and predicting progestin treatment outcomes. [Extracted from the article]

A recent study conducted at Vilnius University Hospital in Lithuania examined the staining patterns of cytokeratins (CKs) in patients with atypical endometrial hyperplasia (AEH) coexisting with early-stage endometrial cancer (EC). The researchers collected specimens from women who underwent surgical interventions between 2012 and 2019 and analyzed the staining patterns of CK7, CK19, CK20, and CK AE1/AE3. The results showed heterogeneous expression of CK7 and CK19 in both AEH and EC specimens, with intense staining observed in the majority of cases. However, CK20 staining was not a characteristic feature of AEH or early-stage EC. The study suggests that analyzing CK staining patterns may aid in the accurate diagnosis of AEH and early-stage EC and improve oncological outcomes. [Extracted from the article]

A study conducted at the Second Hospital of Hebei Medical University in China aimed to evaluate the prognostic ability of mismatch repair deficiency (MMR-d) and abnormal p53 expression (p53abn) in patients with endometrial atypical hyperplasia (EAH) who underwent fertility-preserving treatment. The study found that patients with MMR-d and p53abn had a significantly higher risk of disease relapse and progression. The researchers concluded that MMR-d and p53abn may be used as predictive biomarkers of progestin resistance and endometrial tumorigenesis in EAH. [Extracted from the article]

Researchers from the First Affiliated Hospital of Soochow University in China have developed a few-shot learning (FSL) method to accurately identify non-atypical endometrial hyperplasia (NAEH), atypical endometrial hyperplasia (AEH), and endometrial cancer (EC) based on limited transvaginal ultrasonic (TVU) images. The FSL model, which combines dual pretrained ResNet50 V2 eigenvectors extractor and KNN classifier, achieved high accuracy and precision in diagnosing these conditions. The study suggests that this computer-aided disease diagnosis method has potential for application in clinical settings. [Extracted from the article]

A new report from the Mayo Clinic in Rochester, Minnesota discusses the use of artificial intelligence (AI) to enhance the accuracy of transvaginal ultrasound in detecting endometrial cancer and endometrial atypical hyperplasia. The study aimed to develop an AI-based automated segmentation model and classifier model using transvaginal ultrasound images. The researchers found that the AI algorithm was able to differentiate between endometrial atypical hyperplasia/cancer and benign conditions with a sensitivity of 0.87 and specificity of 0.86. This research has been peer-reviewed and provides promising advancements in the field of AI and women's health. [Extracted from the article]

A recent study conducted at King Abdulaziz University in Jeddah, Saudi Arabia, explored the potential therapeutic benefits of cordycepin (COR) in treating endometrial hyperplasia (EH). EH is a condition characterized by abnormal thickening of the uterine lining. The study found that COR treatment resulted in a significant decrease in endometrial thickening and reduced expression of proliferation markers in uterine tissue. COR also exhibited antioxidant properties and downregulated proteins involved in inflammation. The researchers concluded that COR shows promise as a non-invasive treatment for EH by enhancing antioxidant defenses, reducing inflammation, and modulating the PTEN/PI3K/Akt axis. [Extracted from the article]

A recently issued patent outlines methods and systems for manipulating ovarian tissues to address various female health issues. The patent describes techniques such as mechanical manipulation, chemical agents, energy application, and cooling to overcome the limitations of current surgical procedures. The methods involve the use of an ovarian tissue apparatus, which includes a docking device and a therapeutic element that delivers energy to treat the tissue. Imaging techniques like ultrasound or MRI can guide the procedure, and pre-treatment planning helps determine the target tissue's size and location. This patent has potential applications in treating conditions like polycystic ovary syndrome and infertility. [Extracted from the article]

A recent study conducted by researchers at Zhejiang University School of Medicine explored the role of the uterine microbiome in the development of endometrial hyperplasia (EH), a precursor to endometrial cancer. The study found a significant shift in the uterine microbiome of patients with EH compared to those with benign conditions. The presence of Delftia, Serratia, and Stenotrophomonas bacteria was associated with EH. However, further investigation is needed to determine the potential of these microbes as biomarkers for EH. This research provides valuable insights into the relationship between the uterine microbiome and EH. [Extracted from the article]

A study conducted by Semmelweis University in Budapest, Hungary, aims to evaluate the effectiveness of a combination therapy for treating endometrial hyperplasia or early stage endometrial cancer while preserving fertility. The therapy includes a levonorgestrel intrauterine device (LNG-IUD), metformin, and liraglutide. The study will enroll 264 women aged 18-45 with a BMI > 30. The primary outcomes will focus on complete pathological remission, while secondary outcomes will assess histological changes, glucose and insulin levels, and weight changes over a 12-month period. The researchers hypothesize that the combination therapy may lead to higher regression rates of endometrial hyperplasia and early stage endometrial cancer compared to the LNG-IUD alone, with minimal adverse effects. [Extracted from the article]

A study conducted at Zhejiang University in China aimed to evaluate the rates and risk factors of concurrent endometrial carcinoma in patients with a preoperative diagnosis of atypical endometrial hyperplasia (AEH). The study found that 31.81% of AEH patients had a diagnosis of endometrial cancer in hysterectomy specimens. Factors such as BMI, post-menopausal status, and endometrial thickness were found to be determinants in diagnosing endometrial carcinoma. The study concluded that intraoperative frozen section analysis of AEH could assist in clinical decision-making during surgery. [Extracted from the article]

A recent study conducted at the City of Hope National Medical Center in Duarte, California, has identified a new class of undifferentiated uterine sarcomas associated with SMARCA4/BRG1 deficiency. The study focused on a 34-year-old Asian woman with a SMARCA4/BRG1-deficient uterine tumor that exhibited unique features, including phyllodiform architecture, rhabdoid tumor cells, and cooccurrence with endometrial complex atypical hyperplasia. Molecular analysis revealed mutations in several genes involved in histone modification, chromatin remodeling, and Wnt signaling. The findings expand the understanding of SMARCA4/BRG1-deficient uterine neoplasms and their molecular-morphologic spectrum. [Extracted from the article]

A study conducted by researchers at JSS College of Pharmacy in Tamil Nadu, India, explores the relationship between obesity and endometrial hyperplasia, a condition associated with an increased risk of endometrial and ovarian cancers. The study focuses on the role of adipokines and elevated estrogen levels in activating cell survival signaling pathways in endometrial cells. The researchers also investigate the potential anti-inflammatory and anti-proliferative effects of polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and arachidonic acid (AA) in mitigating obesity-induced endometrial hyperplasia. The study concludes that PUFAs may have a beneficial role in reducing the risk of ovarian cancer and attenuating obesity-associated endometrial hyperplasia. [Extracted from the article]

A recent study conducted at Peking Union Medical College Hospital in Beijing, China, has provided guidelines for the management of endometrial hyperplasia. The study found that endometrial hyperplasia can be classified as either hyperplasia without atypia or atypical hyperplasia, with abnormal uterine bleeding being the most common symptom. The study recommends the use of transvaginal ultrasound for initial imaging and endometrial biopsy to confirm diagnosis. Treatment options include progesterone medication and the placement of a levonorgestrel-releasing intrauterine system (LNG-IUS). Hysterectomy is not the preferred choice of treatment for patients with endometrial hyperplasia without atypia. Patient education is also emphasized to improve medication adherence and lower recurrence rates. [Extracted from the article]

A recent study conducted at Valais Hospital in Sion, Switzerland, aimed to determine the anatomical distribution of sentinel lymph nodes (SLNs) in patients with endometrial cancer (EC) using a retroperitoneal transvaginal natural orifice transluminal endoscopic surgery (vNOTES) approach. The study included 34 patients, with 97.1% having a successful procedure. A total of 124 SLNs were identified and removed, with the majority located in the obturator region. The study found differences in the localization of SLNs compared to laparoscopic mapping. The research was published in the Journal of Minimally Invasive Gynecology. [Extracted from the article]

A study conducted at Erlangen University Hospital in Germany explored the use of laparoscopic sentinel node biopsy (SNB) in patients with early-stage endometrial cancer (EC) and atypical endometrial hyperplasia (AEH). The study found that SNB can be safely offered to patients with precursor lesions and early-stage EC without significantly increasing surgical times or postoperative morbidity. However, the impact of SNB on patients diagnosed with AEH was found to be relatively small. The study highlights the evolving approach to the medical and surgical treatment of EC, emphasizing a more patient-centered and personalized approach. [Extracted from the article]

A recent study conducted by Xuzhou Medical University aimed to identify factors that affect lymphovascular space invasion (LVSI) in endometrial cancer (EC) using machine learning technology. The study collected samples from 312 EC patients and analyzed clinical data and laboratory indicators. The researchers identified independent risk factors for LVSI in EC, such as myometrial infiltration depth, cervical stromal invasion, lymphocyte count, monocyte count, albumin, and fibrinogen. They constructed a risk model based on machine learning that effectively predicts LVSI in EC and enhances preoperative decision-making. The study demonstrates the potential of machine learning in improving the diagnosis and treatment of endometrial cancer. [Extracted from the article]

A new report from Jersey Shore University Medical Center presents fresh data on endometrial hyperplasia. The study aimed to evaluate the efficacy and safety of sentinel lymph node (SLN) sampling in cases of complex atypical endometrial hyperplasia (CAH) managed by the da Vinci robotic platform. The research found that SLN sampling had a high map rate and low complications in CAH, and it recommended further investigation into the clinical benefits of the procedure. The study concluded that a preoperative diagnosis of CAH bordering on or unable to rule out cancer was the only predictor of cancer. [Extracted from the article]

A recent report from Wayne State University discusses the correlation between steroid receptor expression and response to progestin therapy in patients with atypical endometrial hyperplasia (AEH) or endometrial cancer (EMCA). The study found that patients who successfully responded to the treatment showed a significant decrease in immunohistochemistry (IHC) scores after treatment compared to those who did not respond. The researchers suggest that steroid receptor expression could be used as a possible biomarker for response to progestin therapy in patients undergoing conservative management for AEH and EMCA. The study included 15 patients, the majority of whom were of African American ethnicity. [Extracted from the article]

Researchers from the University of the Witwatersrand in South Africa have developed a novel intrauterine device (IUD) for the treatment of the genitourinary syndrome of menopause (GSM). The device is designed to release norethindrone acetate (NETA) in a sustained manner within the uterine cavity, serving as a counter-estrogenic intervention for GSM. The IUD was fabricated using a combination of ethyl cellulose (EC) and polycaprolactone (PCL), and its mechanical properties, drug release, and cytocompatibility were evaluated. The study found that the developed platform showed promising results and holds potential for further biomedical applications. [Extracted from the article]

A study conducted in Jharkhand, India analyzed the histomorphological patterns of the endometrium in post-menopausal women presenting with post-menopausal bleeding. The study found that the most common cause of post-menopausal bleeding was endometrial atrophy, followed by endometrial hyperplasia and endometrial cancer. The highest incidence of post-menopausal bleeding was observed in women under the age of 60, and the incidence of malignancy increased after the age of 57. Proliferative endometrium was the most common finding among benign causes of post-menopausal bleeding, while endometrial adenocarcinoma of the endometroid type was the most frequent malignant cause. [Extracted from the article]

A clinical trial is currently underway in China to evaluate the effectiveness and side effects of a membrane-inhibiting formula combined with oral progestins as a treatment for early-stage endometrial cancer and endometrial hyperplasia in childbearing-age women. The trial aims to determine if the formula can shorten the time required for complete endometrial remission when taken with oral progestins, as well as assess any medical problems participants may experience. The study will also examine the efficacy, side effects, recurrence, pregnancy rates, and time to obtain pregnancy in different molecular classifications of the disease. Participants will take the formula and progestins daily, visit the clinic every 3 months for checkups and tests, and keep a diary of examination results and pathology. The trial is currently recruiting participants and is expected to be completed by December 2026. [Extracted from the article]

A recent study conducted by researchers at the University of Medicine and Pharmacy in Bucharest, Romania, explored the potential use of serological markers as biomarkers for the diagnosis, prognosis, and treatment response of endometrial cancer. The study compared various blood markers in patients with benign or malignant endometrial tumors and found significant differences in serological biomarkers between the two groups. These findings suggest that these biomarkers could be useful in endometrial cancer management and are accessible for analysis in any healthcare system. The study provides valuable insights into the potential role of serological markers in improving the diagnosis and treatment of endometrial cancer. [Extracted from the article]

A recent study conducted at Bichat-Claude Bernard Hospital in Paris, France, explored the pregnancy and obstetric outcomes of women with atypical hyperplasia (AH) or early-stage endometrial cancer (EC) who underwent fertility-sparing treatment. The study found that 62% of patients achieved a live birth after conservative treatment, but there were higher rates of labor induction, caesarean section, and post-partum hemorrhage. The research suggests that fertility-sparing treatments for AH/EC can be successful, but caution should be exercised, potentially leading to more caesarean sections and labor inductions. The study did not find an increase in adverse obstetric outcomes, except for a possible higher risk of post-partum hemorrhaging. [Extracted from the article]

A recent study conducted at MVJ Medical College and Research Hospital in Karnataka, India, examined the expression of Bcl-2 and Ki-67 in endometrial hyperplasia and disordered endometrium. Endometrial hyperplasia is a condition that affects both premenopausal and postmenopausal women and can range from mild glandular proliferations to precursors of cancer. The study found that the overexpression of Bcl-2 in endometrial hyperplasia indicates progression towards malignancy, while Ki-67, a proliferation marker, is used to determine the progression of endometrial hyperplasia to carcinoma. This research provides valuable insights into the biomarkers and diagnostic tools for endometrial hyperplasia. [Extracted from the article]

A recent study conducted by researchers at the University of Opole in Poland examined the role of telomeres and telomerase in endometrial cancer and hyperplasia. The study analyzed samples from 117 patients and found that the control group had the longest telomeres compared to the hyperplasia and endometrial cancer groups. Telomerase expression was only observed in the endometrial cancer group and was positively correlated with telomere length. The researchers concluded that telomere extension in endometrial cancer is mediated by telomerase, but telomere length may not be an indicator of endometrioid cancer development. [Extracted from the article]

A clinical trial is being conducted in the Philippines to investigate the use of the etonogestrel contraceptive implant as a treatment for endometrial hyperplasia without atypia. This condition involves the abnormal thickening of the lining of the uterus and can potentially lead to endometrial cancer. The study aims to determine the rate of regression to normal endometrium among patients with this condition after the insertion of the implant. The researchers propose that the etonogestrel implant may have therapeutic effects on endometrial hyperplasia without atypia, although this has not been studied before. [Extracted from the article]

A recent report discusses research conducted by the CSIR - Indian Institute of Toxicology Research on endometrial hyperplasia. The study focused on the effects of chronic exposure to Zearalenone (ZEA), a natural food contaminant with estrogen-mimicking properties. The research found that ZEA exposure led to changes in the uterus, including hyperplasia and increased gland numbers. Additionally, inflammatory cytokines and proliferation markers were found to be elevated in the ZEA-exposed groups. The study suggests a possible link between ZEA exposure and endometrial toxicity. [Extracted from the article]

A recent study conducted by the University of Southern California (USC) examined the utilization of hysteroscopy for endometrial evaluation in patients with endometrial hyperplasia. The study found that 82.5% of patients underwent hysteroscopic endometrial tissue evaluation, with patients experiencing postmenopausal bleeding, heavy menstrual bleeding, and polycystic ovary syndrome being more likely to undergo this procedure. The study also observed an increase in the utilization of intrauterine device insertion during hysteroscopic endometrial evaluation, particularly among younger patients, those who had surgery more recently, and those who were obese. The research suggests that the insertion of intrauterine devices during hysteroscopic endometrial evaluation for endometrial hyperplasia is increasing among the reproductive-age population. [Extracted from the article]

A recent case study conducted at Hospital Tengku Ampuan Rahimah in Malaysia explored the effectiveness of combining hormone replacement therapy (HRT) with controlled ovarian stimulation to improve endometrial thickness in cases of thin endometrium. The study focused on a 35-year-old patient with primary subfertility and a history of right salphingo-oophorectomy. After struggling with thin endometrium in previous cycles, the patient underwent HRT with tablet progynova and estrogel, followed by low-dose ovarian stimulation with recombinant FSH. The combination of HRT and ovarian stimulation resulted in improved endometrial thickness, leading to a successful frozen embryo transfer and an ongoing pregnancy at 18 weeks. The study concluded that this combination approach allows exogenous and endogenous estrogen to act synchronously on the endometrium, enhancing endometrial thickness for implantation. [Extracted from the article]

A recent report from the Institute of Medical Sciences in Uttar Pradesh, India, presents new data on endometrial hyperplasia. The study aimed to compare the expression of estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu in cases of endometrial hyperplasia and endometrial carcinoma with normal endometrium. The researchers found that ER and PR levels were overexpressed in endometrial hyperplasia and carcinoma compared to normal endometrium, but significantly reduced in adenocarcinoma compared to simple hyperplasia. The study suggests that evaluating the expression of ER and PR could serve as a prognostic marker and guide hormonal therapy in cases of hyperplasia and adenocarcinoma. [Extracted from the article]

A clinical trial has been launched to collect vaginal fluid specimens from participants with endometrial cancer, endometrial hyperplasia with atypia, or endometrial intraepithelial neoplasia. The samples will be used for research and development of a new molecular diagnostic test for the detection of these conditions. The study aims to obtain de-identified samples from women aged 18 and older who have received a histopathological diagnosis of the specified conditions. The trial is currently recruiting participants and is expected to be completed by June 2024. [Extracted from the article]

A researcher at Polytechnic University of Marche has published data on endometrial hyperplasia, a challenging clinical condition. The research focused on factors such as predictive variables of occult endometrial cancer, the rate of cancer underestimation based on different endometrial sampling methods, and the appropriateness of lymph node status assessment. The study found that low-risk endometrial cancer is detected in approximately 90% of cases, while intermediate/high-risk cases are found in 10-13% of women with cancer. Hysteroscopic endometrial resection provided the lowest cancer underestimation rate, and further studies are needed to confirm these findings. The evaluation of lymph node status showed a positivity rate of 2.3%, but the data does not recommend this option based on a cost/risk/benefit ratio. [Extracted from the article]

A report from Wenzhou University in Zhejiang, China discusses the findings of a study on endometrial hyperplasia. The researchers created a novel Co(II) coordination complex and investigated its biological activity against endometrial hyperplasia. The study concluded that the complex showed activity against the given probe protein and may have therapeutic effects on endometrial hyperplasia by inducing endometrial cell apoptosis. The research has been peer-reviewed and provides valuable insights into potential treatments for this condition. [Extracted from the article]

A recent study conducted in Buenos Aires, Argentina, examined the gene transcription of key inflammatory genes and progesterone receptor in bitches with endometritis. The researchers collected uterine biopsies from clinically healthy bitches with a normal endometrium and bitches with endometritis. The study found that the mRNA expression of Cyclooxygenase 1 (COX1), cytokines (Interleukin 6 [IL6], Interleukin 8 [IL8], and Leukemia Inhibitory Factor [LIF]), and Progesterone Receptor (PR) was significantly different between the two groups. The researchers concluded that these biomolecular markers could potentially aid in the diagnosis of endometritis in bitches. [Extracted from the article]

A recent study conducted by researchers at King Saud University in Saudi Arabia explored the use of metabolomic profiling of blood plasma to identify potential biomarkers for endometrial cancer (EC) and benign endometrial hyperplasia. The study involved 59 postmenopausal participants, including those with EC, hyperplasia, and healthy participants. The researchers found that certain metabolites were dysregulated in EC and hyperplasia samples compared to the control group, suggesting that these metabolites could serve as specific markers for these conditions. The study also indicated that endometrial cancer cells may adopt alternative strategies to increase energy production and support proliferation. [Extracted from the article]

A study conducted by researchers at Kermanshah University of Medical Sciences in Iran explores the occurrence of synchronous tumors in gynecologic malignancies, specifically focusing on a case of papillary endometrial adenocarcinoma with cervical dysplasia. The study highlights the importance of thorough sampling and examination in diagnosing and treating gynecologic cancers, as they may be accompanied by other malignancies or premalignant lesions. The research emphasizes that synchronous malignancies often have better prognoses than metastatic lesions and recommends caution and comprehensive evaluation in these cases. For more information, the full article can be accessed through the Asian Pacific Journal of Cancer Biology. [Extracted from the article]

A recent study conducted at Andhra Medical College in Visakhapatnam, India, explored the relationship between obesity, diabetes, and endometrial thickness in postmenopausal women with abnormal uterine bleeding. The study found that endometrial atrophy was the most common finding in women with postmenopausal bleeding, but approximately 10-15% of cases were associated with endometrial carcinoma. The researchers used transvaginal sonography (TVS) to assess endometrial thickness and compared it with histopathological findings. The results showed a statistically significant association between TVS findings and histopathological examination, suggesting that TVS can be a useful diagnostic tool for investigating postmenopausal bleeding in women. [Extracted from the article]

A recent study conducted by investigators at Guangzhou Medical University in Guangdong, China explored the prognostic significance of autophagy-related genes (ARGs) in endometrial cancer (EC). The researchers used bioinformatics to screen differentially expressed ARGs between EC and normal endometrial tissue samples and performed Cox regression analysis to construct risk signatures for overall survival (OS) and progression-free survival (PFS). CDKN2A was identified as a hub prognostic ARG and showed significant associations with various clinical characteristics and immune infiltration. The study suggests that CDKN2A may serve as a prognostic factor and therapeutic target in EC, potentially influencing the tumor immune landscape and autophagy. [Extracted from the article]

A recent study conducted at Kiangwu Hospital in Macau, China, explored the use of the endometrial sampler SAP-1 as a screening tool for endometrial cancer (EC) in patients with a general risk. The study enrolled 275 patients who were hospitalized for hysteroscopy and confirmed to have a general risk of EC. The diagnostic efficacy of SAP-1 sampling was analyzed, and the results showed that SAP-1 had a sensitivity of 88.2%, specificity of 100%, and accuracy of 99.3% in diagnosing endometrial carcinoma and precancerous lesions. The researchers concluded that SAP-1 is a highly efficient and safe method for screening EC in women with a general risk and can be easily performed in outpatient settings. [Extracted from the article]

Researchers at the University of Texas Southwestern Medical Center have found that a panel of immunohistochemical markers consisting of PAX2, PTEN, and beta-catenin can effectively identify atypical hyperplasia/endometrioid intraepithelial neoplasia (AH/EIN) within endometrial polyps (EMPs). The study analyzed 105 cases of AH/EIN within EMPs and found that aberrant expression of at least one marker was observed in 92.4% of cases, with 60% showing abnormal results for two or more markers. The prevalence of PAX2 aberrancy was significantly lower in AH/EIN in EMPs compared to nonpolyp AH/EIN, but higher than in benign EMPs. The researchers concluded that the 3-marker panel is a useful tool in diagnosing AH/EIN in EMPs, but caution should be exercised when interpreting PAX2 loss. [Extracted from the article]

A recent study conducted at the Vijayanagar Institute of Medical Sciences focused on serous carcinoma, a rare variant of endometrial cancer that primarily affects postmenopausal women. Serous carcinoma is characterized by aggressive tumor growth and metastasis, making early diagnosis crucial for effective management. The study found that the TP53 tumor suppressor gene mutation is an early event in the development of serous endometrial carcinoma. The researchers recommend that postmenopausal women at risk should undergo endometrial biopsies for early detection and treatment, as serous carcinoma accounts for a significant proportion of endometrial cancer-related deaths. [Extracted from the article]

A new report discusses research on endometrial hyperplasia, a condition that can lead to endometrial cancer in women. The study aimed to assess the predictive value of patient characteristics in determining the risk of endometrial cancer in women with atypical endometrial hyperplasia (AEH). The research found that patient characteristics, such as age, body mass index, Lynch syndrome, diabetes, and previous breast cancer, did not show satisfactory performance in predicting endometrial cancer in AEH. The study suggests that risk stratification based solely on patient characteristics may not be clinically suitable. [Extracted from the article]

A recent study conducted by researchers at Erciyes University in Kayseri, Turkey, examined the prognostic value of lymph node features in patients diagnosed with stage IIIC endometrial adenocancer (EAC). The study analyzed the records of 120 patients with EAC who underwent hysterectomy and systematic retroperitoneal lymphadenectomy between 2009 and 2019. The researchers found that large-sized metastatic lymph nodes were an independent prognostic factor for disease-free survival and overall survival in patients with stage IIIC EAC. However, further studies are needed to confirm these findings. The study was published in the Journal of Cancer Research and Therapeutics. [Extracted from the article]

A study conducted by the Medical University of Vienna has found that the gene MLLT11 may play a role in the development and progression of endometriosis. The researchers analyzed the expression of MLLT11 in women with and without endometriosis and found that it was reduced in the ectopic stroma cells of women with advanced stage endometriosis. Knockdown of MLLT11 in control stroma cells resulted in decreased proliferation, increased apoptosis resistance, and increased cell adhesion. These findings suggest that MLLT11 may be a clinically relevant factor in the pathogenesis of endometriosis. [Extracted from the article]

A recent study conducted at the Memorial Sloan-Kettering Cancer Center in New York City explored the association between molecular subtype and progesterone response in patients with endometrial cancer (EC) or atypical endometrial hyperplasia (AEH). The study found that molecular subtype may be linked to progesterone response, with copy number-low (CN-L) tumors showing the best response and microsatellite instability-high (MSI-H) tumors showing the poorest response. The study also noted that recurrence after complete response (CR) is common and emphasized the need for close surveillance. Larger studies are needed to further investigate the role of molecular classification in the medical management of EC/AEH. [Extracted from the article]

A patent has been issued for a new implant system designed to treat gynecological malignancies. The system includes a surgical instrument and an implant that can be separated from the instrument and positioned within the uterus. The implant contains a bioactive agent, such as a chemotherapeutic or hormonal agent, which is administered to the endometrium to treat the malignancy. The implant can be made of a bioresorbable material and may have semi-permeable properties. This patent provides a potential new treatment option for gynecological cancers and conditions. [Extracted from the article]

A recent report from the University of Texas Austin highlights the prevalence of endometrial carcinoma (EC) as the most common gynecological malignancy in the United States. The study focuses on the role of dihydroorotate dehydrogenase (DHODH) in cancer cell DNA replication and its impact on treatment response. The research reveals that endometrial tumors with overexpression of DHODH are associated with a high mutation count and chromosomal instability. Inhibition of DHODH in endometrial cancer cell lines induces replication-associated DNA damage and hinders replication fork progression, making DHODH a potential target for enhancing cytotoxicity in high-grade endometrial tumors. [Extracted from the article]

A recent study conducted by researchers at the Karolinska Institute in Stockholm, Sweden, compared the characteristics of pre- and postmenopausal women diagnosed with endometrial cancer. The study analyzed data from the International Endometrial Tumor Analysis (IETA) 4 cohort, which included 1,538 women with biopsy-confirmed endometrial cancer. The findings revealed that premenopausal women had lower parity, a higher family history of colon cancer, and smaller waist circumferences compared to postmenopausal women. Premenopausal women also exhibited certain sonographic features more frequently, such as a regular endometrial-myometrial border and a visible endometrial midline. However, despite experiencing a longer duration of abnormal uterine bleeding, premenopausal women more often had low-risk disease. The study highlights the importance of considering menopausal status when evaluating sonographic features in women with endometrial cancer. [Extracted from the article]

A recent study conducted at Kagoshima University in Japan reported on the first surgery for gynecological diseases using a new robotic platform called the hinotori surgical robot system. The study aimed to validate the feasibility of this new system in clinical settings. The surgical team successfully performed robot-assisted total hysterectomy on one patient with a gynecological ailment, followed by eleven other patients. The study concluded that robotic surgery with the hinotori system is a feasible technique for minimally invasive surgery in gynecological diseases. The research was supported by Sysmex Corporation and has been peer-reviewed. [Extracted from the article]